Cantargia AB (publ) (CANTA) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Kandarja Q3 Report 2025 presentation. During the questions and answers session, participants are able to ask questions by dialing pound key five on their telephone keypad. Now I will hand the conference over to the speakers, CEO Hilde Steininger and CFO Patrik Renblad. Please go ahead. Thank you. Can you see the slides? I cannot see it. All right. Good afternoon, everyone. And thank you for joining the presentation of our financial report for the third quarter and an update from the company. My name is Hilde Steininger. And as you probably are aware, newly appointed as CEO of Contariga. Next slide. Patrick, may I ask you to change the slides? All right. Slide two, safe harbor. And slide three. Patrick? Okay, let me just finish. With me today, we have our newly appointed medical officer, Dr. Wolfram Dembke, and our CFO, Patrik Renblad. Slide four. We reported this morning our interim report for the third quarter and the first nine months of the year. It has indeed been a transformative period for the company with the Otsuka transaction as the main event. About the same time. About the same period, we communicated the over a primary endpoint from our TRIFOR phase two study on the objective response rate, ORR. And the results show no difference in ORR between the control group treated with chemotherapy and the patients treated with Nadenolumab in combination with chemo. We are awaiting the mature overall survival data, which is expected around year end 2025. I joined Contarga as CEO on September 1st, and I have extensive experience from leadership roles in the pharmaceutical R&D and business development, as well as background in the financial sector as an analyst and venture capitalist. I'm also very happy to introduce Dr. Dempke, who's joined Contaria as chi...